Journal of cannabis research最新文献

{"title":"Anthocyanin accumulation, inflorescence dry weight and total cannabidiol content have different temperature optima in Cannabis sativa.","authors":"Sean R Kim, Pawan Basnet, Al P Kovaleski, Shelby L Ellison","doi":"10.1186/s42238-025-00311-w","DOIUrl":"10.1186/s42238-025-00311-w","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"51"},"PeriodicalIF":4.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of cannabis use on ageing and longevity: a systematic review of research insights.","authors":"Sonam Nain, Niraj Singh, Anne Katrin Schlag, Michael Barnes","doi":"10.1186/s42238-025-00267-x","DOIUrl":"10.1186/s42238-025-00267-x","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"52"},"PeriodicalIF":4.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green solvent-based extraction of Cannabis sativa L. by-products: enhancing antioxidant potential and cannabinoid enrichment using MCT oil.","authors":"Nipaporn Meepun, Ubonta Sommart, Oraporn Bualuang","doi":"10.1186/s42238-025-00309-4","DOIUrl":"10.1186/s42238-025-00309-4","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"50"},"PeriodicalIF":4.3,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The biosynthesis of the cannabinoids.","authors":"M Nazir Tahir, Farsheed Shahbazi Raz, Simon Rondeau-Gagné, John F Trant","doi":"10.1186/s42238-025-00292-w","DOIUrl":"10.1186/s42238-025-00292-w","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"49"},"PeriodicalIF":4.3,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding motives for illicit medicinal cannabis use: an exploratory analysis in a medical cannabis program.","authors":"Carter Reeves, Lirit Franks, A Taylor Kelley, Michael Incze, Adam J Gordon, Ziji Yu, Eden Flake, Gerald Cochran","doi":"10.1186/s42238-025-00284-w","DOIUrl":"10.1186/s42238-025-00284-w","url":null,"abstract":"<p><strong>Background: </strong>Medical Cannabis (MC) is authorized in numerous state-legislated programs to treat approved medical conditions. Notwithstanding MC access, some participants continue to use cannabis purchased outside of a state licensed MC pharmacy, otherwise known as illicit medicinal cannabis (IMC), to treat their medical conditions. Identifying barriers and contributors to MC use and motives for IMC use can promote safety, improve program design, and inform future research efforts.</p><p><strong>Methods: </strong>This exploratory analysis utilized baseline survey data from a convenience sample-based prospective cohort evaluation of newly registered (< 6 months) adult participants in Utah's MC program who had been diagnosed with chronic pain, post-traumatic stress disorder, and/or cancer. Participants completed surveys assessing physical and mental health, program experience, and barriers and contributors to MC access. We employed descriptive analysis, chi-squared analysis, and logistic regression to identify factors influencing IMC use.</p><p><strong>Results: </strong>Among 273 MC program participants screened for eligibility, 227 were enrolled in the cohort evaluation, and 211 participants completed the baseline survey. Approximately 1 in 10 survey respondents (N = 24, 11.9%) reported IMC use within the past two weeks. Participants accessing IMC were 40.5 years old, 58.3% male, 70.8% employed, and 87.5% white. Participants using IMC reported barriers to MC, including product cost (n = 19, 79%) and assurance of adequate supply (n = 11, 45.8%) as the most common motives for IMC use. Participants who reported experiencing MC access barriers were significantly more likely to report IMC use than those reporting no barriers (Odds Ratio (OR) = 4.73, p <.001). Participants using IMC reported lower levels of trust in (p <.04) and reliance (p <.02) upon the state program and less reliance on MC pharmacists (p's < 0.01). However, participants who relied on the state program for MC information were less likely to report IMC use (Adjusted Odds Ratio AOR = 0.16, p <.05).</p><p><strong>Conclusions: </strong>In a state MC program, barriers related to MC access and cost indicated a significant increase in the likelihood of IMC use, while reliance on the state program for MC information indicated a significant decrease in the likelihood of IMC use. Future research can explore how increasing affordable access to MC and availability of reliable information may affect IMC use.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"48"},"PeriodicalIF":4.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-parasitic nematodes on hemp in the Pacific Northwest of the United States.","authors":"Lester A Núñez-Rodríguez, Hannah M Rivedal, Cynthia M Ocamb, David H Gent, Inga A Zasada","doi":"10.1186/s42238-025-00301-y","DOIUrl":"10.1186/s42238-025-00301-y","url":null,"abstract":"<p><strong>Background: </strong>Plant-parasitic nematodes are one of the most important biotic factors that impact crop production globally. Since hemp cultivation in the U.S. was banned from 1970 to 2018, little information is available about current plant-parasitic nematode pressure on U.S. hemp production. The production of hemp has gained interest in Washington and Oregon, states where several genera of plant-parasitic nematodes have been associated with various crops. This report is the first to define plant-parasitic nematodes associated with hemp in these states in the Pacific Northwest.</p><p><strong>Methods: </strong>Soil and root samples from hemp fields were collected in early autumn in 2021, 2022, and 2023. The occurrence, population density, and identity of plant-parasitic nematodes in these samples were determined using morphological and molecular identification methods. A Bayesian analysis of available sequence data was used to analyze phylogenetic relationships of nematode species found in hemp fields. Additionally, the host status of hemp 'Alpha Explorer' to three plant-parasitic nematodes, Meloidogyne chitwoodi, M. hapla, and Pratylenchus neglectus, was tested under greenhouse conditions. The occurrence of plant-parasitic nematodes and reproduction factor (final population density/initial population density) values of the three nematode species were analyzed with non-parametric methods.</p><p><strong>Results: </strong>Pratylenchus spp. were the most frequent plant-parasitic nematodes recovered from soil samples, being present in ~ 63% of samples (n = 107). Only two endoparasitic nematodes, Meloidogyne spp. and Pratylenchus spp., were found in root samples, with Pratylenchus spp. as the most frequent (20 out of 24 fields). A large diversity of Pratylenchus spp. was detected in hemp root samples. Hemp 'Alpha Explorer' was a poor host for P. neglectus, resulting in low reproduction values (< 1). Additionally, results of our study indicated that hemp is not a host for M. chitwoodi.</p><p><strong>Conclusions: </strong>Pratylenchus spp. were the most frequent plant-parasitic nematodes found in hemp fields in Oregon and Washington. This study reports for the first time five Pratylenchus species (Pratylenchus crenatus, P. fallax, P. hexincisus, P. neglectus, and P. scribneri) associated with hemp in Oregon and Washington; P. penetrans was also found in the region on hemp. The host status results indicate that hemp can be considered a non-host for M. chitwoodi and a poor host for M. hapla and P. neglectus.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"47"},"PeriodicalIF":4.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and factors among oncology fellows recommending medical cannabis to adults with cancer.","authors":"Kian Tehranchi, Rushad Patell, Poorva Bindal, Laura Dodge, Jason Freed, Mary Buss, Mara A Schonberg, Ilana Braun, Deepa Rangachari","doi":"10.1186/s42238-025-00293-9","DOIUrl":"10.1186/s42238-025-00293-9","url":null,"abstract":"<p><strong>Background: </strong>Medical cannabis consumption is rising, but limited evidence informs the safety and efficacy of cannabis use in cancer patients. A national survey of oncology trainees found that most fellows felt insufficiently informed to make clinical recommendations about cannabis.</p><p><strong>Aim: </strong>In this secondary analysis, we aimed to measure how frequently trainees recommend in favor of cannabis and determine factors influencing this clinical practice.</p><p><strong>Methods: </strong>In this cross-sectional survey study for fellows enrolled in oncology training programs across the United States, an online survey assessing trainee practices regarding medical cannabis was sent to 155 oncology fellowship program directors from January - March 2021; who were asked to distribute it to their fellows. The primary outcome was the frequency with which oncology fellows recommended cannabis in the prior year.</p><p><strong>Results: </strong>Nationally, 40 programs from 25 states participated, with 189 of 462 trainees across these programs responding (40.9% response rate). 22% (95% CI: 16.3-29.0%) of participants reported recommending medical cannabis to > 5 patients in the past year. 24% (95% CI: 18.4-30.5%) of participants had prior training in medical cannabis. Regarding participant characteristics, only prior training in medical cannabis was significantly associated with recommending cannabis to > 5 patients (RR: 2.4; 95% CI: 1.4-4.2).</p><p><strong>Conclusions: </strong>With increasing cannabis use among patients with cancer and given that a substantial number of oncology fellows recommend its use, it is crucial that fellowship training incorporate evidence-based curricula regarding medical cannabis use to guide informed decision-making between patients and their fellow providers.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"45"},"PeriodicalIF":4.1,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of five cannabis oils with different CBD: THC ratios and terpenes on hypertension, dyslipidemia, hepatic steatosis, oxidative stress, and CB1 receptor in an experimental model.","authors":"Valentina Degrave, Michelle Berenice Vega Joubert, Camila Filippa, Paola Ingaramo, Lucía Torregiani, Yamile Soledad Caro, María Mercedes De Zan, María Eugenia D'Alessandro, María Eugenia Oliva","doi":"10.1186/s42238-025-00286-8","DOIUrl":"10.1186/s42238-025-00286-8","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder caused by oxidative stress and dysregulation of lipid metabolism. The endocannabinoid system (ECS), particularly the type 1 cannabinoid (CB1) receptor, plays a crucial role in NAFLD progression. Cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), along with terpenes, such as beta-myrcene and d-limonene, have shown potential therapeutic effects on liver health, particularly in reducing oxidative stress and modulating lipid metabolism. This study aimed to analyse the effects of five cannabis oils (COs), each with different CBD:THC ratios and terpenes content, on hypertension, dyslipidemia, hepatic steatosis, oxidative stress, and CB1 receptor expression in an experimental model of NAFLD induced by a sucrose-rich diet (SRD) in Wistar rats for 3 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Male Wistar rats were fed either a: (1) reference diet (RD; standard commercial laboratory diet) or a: (2) sucrose-rich diet (SRD) for 3 weeks. 3 to 7 SRD + CO as following: (3) SRD + THC; (4) SRD + CBD; (5) SRD + CBD:THC 1:1; (6) SRD + CBD:THC 2:1; and (7) SRD + CBD:THC 3:1. The COs were administered orally at a dose of 1.5 mg total cannabinoids/kg body weight daily. The cannabinoid and terpenes content of all COs used in the study was determined. The terpenes found in COs were beta-myrcene, d-limonene, terpinolene, linalool, beta-caryophyllene, alpha-humulene, (-)-guaiol, (-)-alpha-bisabolol. During the experimental period, body weight, food intake and blood pressure were measured. Serum glucose, triglyceride, total cholesterol, uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (AP) levels were evaluated. Liver tissue histology, NAFLD activity score (NAS), triglyceride and cholesterol content, lipogenic enzyme activities, enzyme related to mitochondrial fatty acid oxidation, reactive oxygen species (ROS), thiobarbituric acid reactive substance (TBARS), and antioxidant enzyme activities were also evaluated. The CB1 receptor expression was also determined.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The results showed that SRD-fed rats developed hypertension, dyslipidemia, liver damage, hepatic steatosis, lipid peroxidation, and oxidative stress. This was accompanied by upregulation of liver CB1 receptor expression. CBD-rich CO, CBD:THC 1:1 ratio CO; CBD:THC 2:1 ratio CO and CBD:THC 3:1 ratio CO showed antihypertensive properties. THC-rich CO, CBD:THC 1:1 ratio CO; CBD:THC 2:1 ratio CO showed the greatest beneficial effects against hepatic steatosis and liver damage. All COs exhibited antioxidant effects in liver tissue. This was associated with normal liver CB1 receptor expression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This study demonstrated that COs, particularly THC-rich CO, CBD:THC ratio 1:1 CO, CBD:THC ratio 2:1 CO and terpenes, can effectively reduce dyslipidemia, liver damage and hepatic steatosis in SRD-in","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"46"},"PeriodicalIF":4.1,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of medicinal cannabis prescriptions in diverse patient populations: a retrospective analysis.","authors":"Omer Edni, Eviatar Naamany, Shimon Izhakian, Shachaf Shiber","doi":"10.1186/s42238-025-00307-6","DOIUrl":"10.1186/s42238-025-00307-6","url":null,"abstract":"<p><strong>Introduction: </strong>The use of medicinal cannabis is increasing worldwide and has applications in managing a wide range of conditions, including neurological, rheumatological, and gastrointestinal diseases. Despite its growing prevalence, there are limited data on patterns of cannabis prescription across varying disease groups and demographic subgroups.</p><p><strong>Methods: </strong>This retrospective observational cohort study analysed cannabis usage patterns among 263 patients from the cannabis user clinic at Rabin Medical center (RMC), a tertiary hospital in Israel. To minimise the inclusion of recreational cannabis users, only patients aged 30 years and older were included. Patients were categorised into three groups based on their primary medical condition: neurological (n = 63), rheumatological (n = 106), and gastrointestinal (n = 94). Data collected included: demographic information, cannabis dosage, Tetrahydrocannabinol (THC) content, cultivated variety preference (sativa vs. Indica), and method of consumption (smoking vs. oil). Statistical analyses were conducted using ANOVA, Kruskal-Wallis, chi-square, and t-tests to compare cannabis prescription patterns between disease and demographic groups.</p><p><strong>Results: </strong>Significant differences in cannabis prescription patterns were observed across disease groups. Patients with gastrointestinal conditions were prescribed the highest mean monthly cannabis dose (22.26 ± 13.60 g), while those with neurological conditions had the highest oil consumption (31.75%). Sex-based differences were notable, with male patients being prescribed significantly higher doses of cannabis (25.48 ± 15.15 g) and higher THC content (14 ± 6.56%) compared to female patients (17.32 ± 9.93 g; THC: 11.39 ± 6.48%).</p><p><strong>Discussion: </strong>The study highlights variations in cannabis prescription patterns based on both medical conditions and demographic factors. Male patients received higher doses and THC-rich formulations, while patients with gastrointestinal conditions had the highest cannabis prescription overall. These findings suggest the need for individualised cannabis therapy based on patient characteristics and the specific condition being treated.</p><p><strong>Conclusion: </strong>Medicinal cannabis usage patterns vary significantly across disease and demographic groups. Personalised cannabis treatment plans, informed by both clinical and demographic factors, are essential to optimising patient outcomes. Further research is needed to develop more precise guidelines for prescribing medicinal cannabis.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"43"},"PeriodicalIF":4.1,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal and combined medicinal/recreational cannabis use in California following the passage of Proposition 64.","authors":"Daniel Ageze, Renee Dell'Acqua, Thomas D Marcotte, Jill Rybar, Sara Baird, Alice Gold, Tom Shaughnessy, Ilene Lanin-Kettering, Linda Hill","doi":"10.1186/s42238-025-00285-9","DOIUrl":"10.1186/s42238-025-00285-9","url":null,"abstract":"<p><strong>Background: </strong>Proposition 64, the Adult Use of Marijuana Act of 2016, reshaped cannabis use in California. This study explores the use patterns of people who use cannabis for medicinal-only and combined medicinal and recreational use after implementation of Proposition 64.</p><p><strong>Methods: </strong>A quantitative, population-based online questionnaire included 4,020 current cannabis users, 523 former users, and 635 non-users. This analysis focuses on participants who self-identified as using cannabis for medicinal-only (n = 711) or both medicinal and recreational (M + R, n = 1719) purposes.</p><p><strong>Results: </strong>Sixty one percent of current cannabis users report medicinal use. Medicinal-only users were more likely to be female (OR 1.6, p < 0.001), have kids in household (OR 1.5, p < 0.001), and began cannabis use later (mean age 34 vs. 23, p < 0.001). Pain relief was the predominant reason for use, followed by sleep, anxiety, and stress relief. While both groups reported positive effects, M + R users experienced more negative side effects. Fewer medicinal-only users cited a desire to \"feel the high,\" (42% vs. 75% M + R, p < 0.001). Medicinal-only users felt less comfortable discussing cannabis with primary care providers than M + R users (75% vs 83%, p < 0.01). All users were more likely to seek information online (44-57%) or from friends/family (47-52%) than health professionals (26-27%). Dispensaries were the main cannabis source for both medicinal groups (72% M vs. 84% M + R, p < 0.01), with licensure being very or extremely important (72% M, 66% M + R, p < 0.01). Monthly spending for medicinal-only users was lower ($127 vs. $186 for M + R, p < 0.001), and they were more likely than M + R users to wait before feeling safe to drive after using cannabis.</p><p><strong>Conclusion: </strong>People who use medicinal cannabis alone vary in key areas from people who use cannabis for both medicinal and recreational reasons. The need for better patient-provider relationships and clinically informed guidance is evident to support medicinal cannabis users.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"44"},"PeriodicalIF":4.1,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}